Intestinal Research

Original Article

IBD

Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study: Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal; Intest Res 2022;20(4):445-451. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00106

Background/Aims
Response to vaccine in patients with inflammatory bowel disease is lower than in the general population. We aimed to evaluate the efficacy of hepatitis B virus (HBV) vaccination in patients with ulcerative colitis (UC) versus controls.
Methods
We prospectively compared antibody response to HBV vaccination in 100 patients with UC versus controls. HBV vaccination was given to all the cases and controls at 0, 1 and 6 months. Anti-hepatitis B surface (anti-HBs) titers were then measured 4 weeks after the first and the third dose. Adequate immune response (AIR) was considered if the anti-HBs titer was >10 IU/L and effective immune response (EIR) if the anti-HBs titer was >100 IU/L.
Results
Median anti-HBs titer was lower in patients with UC than controls (67 IU/L vs. 105 IU/L, P<0.01). AIR and EIR were significantly lower in patients than in controls (82% vs. 96%, P=0.001; 41% vs. 66%, P<0.001, respectively). Univariate analysis showed that age <30 years, mild to moderate severity of disease, disease duration <5 years, male sex, post first dose anti-HBs titer >2 IU/L and non-exposure to corticosteroids, azathioprine and biologicals were predictors of AIR in patients with UC (P<0.05). Multivariate analysis revealed that only non-exposure to corticosteroids, azathioprine and biologicals, male sex, and disease duration <5 years were independent predictors of AIR.
Conclusions
Response rate to the HBV vaccination in patients with UC was significantly lower as compared to the controls. Male sex, shorter disease duration, and non-exposure to immunomodulators were independent predictors of AIR.

Citations

Citations to this article as recorded by

Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Rupert W. Leong, Anthony Sakiris, Arteen Arzivian, John David Chetwood, Thanaboon Chaemsupaphan, Miles P. Sparrow, Michael A. Kamm, Viraj Kariayawasam
Alimentary Pharmacology & Therapeutics.2025; 61(1): 132. CrossRef
Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Vaccines.2024; 12(4): 364. CrossRef
Beyond the survey, to the ideal therapy for Asian
Ki Jae Jo, Jong Pil Im
Intestinal Research.2023; 21(3): 280. CrossRef

5,078 View
482 Download
3 Web of Science
3 Crossref

Case Reports

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis: K Arivarasan, Vaishali Bhardwaj, Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri; Intest Res 2016;14(4):365-368. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.365

Abstract PDF PubReader

Pyoderma gangrenosum (PG) is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD). Despite limited published literature, biologics have caused a paradigm shift in the management of this difficult-to-treat skin condition. The clinical data and outcomes of three patients with active ulcerative colitis and concurrent PG treated with biologics (infliximab two and adalimumab one) are reviewed in this report. Biologics were added because of the sub-optimal response of the colonic symptoms and skin lesions to parenteral hydrocortisone therapy. All three patients showed a dramatic response to the addition of the biologics. In view of the rapid healing of the skin lesions, superior response rate, and the additional benefit of improvement in the underlying colonic disease following treatment, anti-tumor necrosis factor blockers should be considered as a first line therapy in the management of PG with underlying IBD.

Citations

Citations to this article as recorded by

Multiple extraintestinal manifestations in a patient with acute severe ulcerative colitis: a case report
Eun Young Park, Dong Hoon Baek, Seung Min Hong, Geun Am Song
Kosin Medical Journal.2022; 37(4): 361. CrossRef
Effective use of switching biologics for ulcerative colitis complicated with pyoderma gangrenosum and primary sclerosing cholangitis
Kenta Iwahashi, Yuichiro Kuroki, Yuichi Takano, Masatsugu Nagahama
BMJ Case Reports.2021; 14(5): e241744. CrossRef
Treatment of Pyoderma Gangrenosum in Pediatric Inflammatory Bowel Disease
Katherine Vaidy, Rebecca Winderman, Simon S. Rabinowitz, Steven M. Schwarz
JPGN Reports.2020; 1(2): e008. CrossRef
Idiopathic pyoderma gangrenosum or a systemic disease predictor?
Todor Yordanov, Jenya Dimitrova, Ivanka Temelkova, Tsveta Kalinova, Neli Koleva, Sonya Marina
Scripta Scientifica Medica.2020; 52(3): 27. CrossRef
Biologic and small-molecule medications in the management of pyoderma gangrenosum
Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings, Alex G. Ortega-Loayza
Journal of Dermatological Treatment.2019; 30(3): 264. CrossRef
Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review
Hakim Ben Abdallah, Karsten Fogh, Rikke Bech
International Wound Journal.2019; 16(2): 511. CrossRef
Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature
Federico Diotallevi, Anna Campanati, Giulia Radi, Valerio Brisigotti, Elisa Molinelli, Donatella Brancorsini, Annamaria Offidani
Dermatologic Therapy.2019; : e12928. CrossRef
A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe
Medina G. Saffie, Anjali Shroff
Case Reports in Infectious Diseases.2018; 2018: 1. CrossRef
Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis
Hyun Il Seo, Hyun-Ju Lee, Koon Hee Han
Intestinal Research.2018; 16(1): 155. CrossRef
A RARE CASE OF CROHN DISEASE COMPLICATED WITH STEROID MONOTHERAPY-RELATED RETROPHARYNGEAL ABSCESS AND INITIALLY MISINTERPRETED PYODERMA GANGRENOSUM DEVELOPMENT
Michael Doulberis, Jörg Dähn, Jannis Kountouras, Volker Maier, Arthur Helbling, Patrick Dubach
Gastroenterology Nursing.2018; 41(4): 347. CrossRef
Successful treatment with tacrolimus of refractory pyoderma gangrenosum with pouchitis after restorative proctocolectomy for ulcerative colitis
Miwa Satake, Hirotake Sakuraba, Hiroto Hiraga, Natsumi Tarakita, Yui Akemoto, Shinji Ota, Keisuke Hasui, Daisuke Nishiya, Shiro Hayamizu, Hidezumi Kikuchi, Manabu Sawaya, Daisuke Chinda, Tatsuya Mikami, Tadashi Shimoyama, Shinsaku Fukuda
Immunological Medicine.2018; 41(3): 142. CrossRef

6,559 View
60 Download
8 Web of Science
11 Crossref

Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis: Jatinderpal Singh, Amarender S Puri, Sanjeev Sachdeva, Puja Sakhuja, Kulandaivelu Arivarasan; Intest Res 2016;14(2):183-186. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.183

Abstract PDF PubReader ePub

Tumor necrosis factor-α inhibitors are now considered as standard therapy for patients with severe inflammatory bowel disease who do not respond to corticosteroids, but they carry a definite risk of reactivation of tuberculosis. We present a case in which a patient with inflammatory bowel disease developed a de novo tuberculosis infection after the start of anti-tumor necrosis factor-α treatment despite showing negative results in tuberculosis screening. Although there are many case reports of pleural, lymph nodal and disseminated tuberculosis following infliximab therapy, we present the first case report of rectal tuberculosis following infliximab therapy.

Citations

Citations to this article as recorded by

Rectal tuberculosis: A systematic review
Poras Chaudhary, Ashutosh Nagpal, Sam B. Padala, Mangarai Mukund, Lalit K. Bansal, Romesh Lal
Indian Journal of Tuberculosis.2022; 69(3): 268. CrossRef
A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis
Shuhei Hosomi, Naoko Sugita, Atsushi Kanamori, Masaki Ominami, Koji Otani, Noriko Kamata, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Yasuhiro Fujiwara
Clinical Journal of Gastroenterology.2022; 15(3): 592. CrossRef
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intestinal Research.2021; 19(4): 419. CrossRef
Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population
Soumajyoti Sarkar, Saumya Panda, Byungsoo Kim, SmritiK Raychaudhuri, Asutosh Ghosh, SibaP Raychaudhuri
Indian Journal of Dermatology, Venereology and Leprology.2020; 86(1): 1. CrossRef
Tuberculosis rectal: presentación clínica infrecuente y diagnóstico diferencial con enfermedad de Crohn
M. Gompertz, L. Carreño, L.C. Gil La Rotta
Revista de Gastroenterología de México.2019; 84(4): 524. CrossRef
Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy
Gen Takahashi, Hiroyuki Kobayashi, Yasuyuki Saito, Sho Ohsawa, Kuniaki Suzuki, Shinichi Ishihara, Takeshi Hisada
Internal Medicine.2019; 58(24): 3593. CrossRef
Rectal tuberculosis: An uncommon clinical presentation and differential diagnosis with Crohn's disease
M. Gompertz, L. Carreño, L.C. Gil La Rotta
Revista de Gastroenterología de México (English Edition).2019; 84(4): 524. CrossRef
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Intestinal Research.2018; 16(1): 4. CrossRef
Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Journal of Gastroenterology and Hepatology.2018; 33(1): 20. CrossRef

5,260 View
41 Download
7 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search